16,300 Shares in ICU Medical, Inc. (NASDAQ:ICUI) Bought by Quantedge Capital Pte Ltd

Quantedge Capital Pte Ltd purchased a new stake in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,300 shares of the medical instruments supplier's stock, valued at approximately $2,529,000. Quantedge Capital Pte Ltd owned 0.07% of ICU Medical at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Occudo Quantitative Strategies LP bought a new stake in ICU Medical in the 4th quarter valued at $911,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of ICU Medical by 4.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,204 shares of the medical instruments supplier's stock valued at $1,894,000 after buying an additional 478 shares during the period. Gotham Asset Management LLC grew its position in ICU Medical by 22.3% during the fourth quarter. Gotham Asset Management LLC now owns 40,610 shares of the medical instruments supplier's stock worth $6,301,000 after buying an additional 7,410 shares in the last quarter. FORA Capital LLC bought a new position in ICU Medical during the fourth quarter valued at about $488,000. Finally, Deutsche Bank AG raised its holdings in ICU Medical by 41.1% in the 4th quarter. Deutsche Bank AG now owns 21,792 shares of the medical instruments supplier's stock valued at $3,381,000 after acquiring an additional 6,345 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Price Performance

ICUI stock traded down $1.82 during trading on Tuesday, hitting $136.19. The company had a trading volume of 56,259 shares, compared to its average volume of 268,698. ICU Medical, Inc. has a fifty-two week low of $100.91 and a fifty-two week high of $196.26. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The company has a fifty day moving average price of $140.78 and a two-hundred day moving average price of $153.61. The company has a market cap of $3.35 billion, a P/E ratio of -29.80 and a beta of 0.87.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.49. The company had revenue of $599.49 million during the quarter, compared to the consensus estimate of $574.15 million. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. The firm's quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.96 earnings per share. Equities research analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

ICUI has been the topic of several recent research reports. Raymond James decreased their price objective on ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a report on Friday, May 9th. KeyCorp reduced their target price on ICU Medical from $209.00 to $191.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. StockNews.com raised shares of ICU Medical from a "hold" rating to a "buy" rating in a report on Sunday. Finally, Needham & Company LLC restated a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, ICU Medical currently has a consensus rating of "Buy" and an average target price of $192.67.

Insider Transactions at ICU Medical

In other news, insider Ben Sousa sold 2,000 shares of the company's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $137.36, for a total value of $274,720.00. Following the completion of the sale, the insider now directly owns 479 shares of the company's stock, valued at $65,795.44. This represents a 80.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David C. Greenberg sold 1,942 shares of ICU Medical stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $143.66, for a total transaction of $278,987.72. Following the transaction, the director now directly owns 6,760 shares in the company, valued at $971,141.60. The trade was a 22.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,208 shares of company stock worth $2,926,969 in the last quarter. 1.50% of the stock is owned by company insiders.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.